XENE icon

Xenon Pharmaceuticals

34.70 USD
-0.41
1.17%
At close Apr 21, 4:00 PM EDT
Pre-market
34.99
+0.29
0.84%
1 day
-1.17%
5 days
8.74%
1 month
-1.81%
3 months
-10.98%
6 months
-21.51%
Year to date
-13.62%
1 year
-13.27%
5 years
168.58%
10 years
132.73%
 

About: Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Employees: 327

0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

5,216% more call options, than puts

Call options by funds: $4.36M | Put options by funds: $82K

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

44% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 13 (+4) [Q4]

3% more funds holding

Funds holding: 201 [Q3] → 208 (+7) [Q4]

1.24% more ownership

Funds ownership: 98.82% [Q3] → 100.06% (+1.24%) [Q4]

1% more capital invested

Capital invested by funds: $2.95B [Q3] → $2.99B (+$41.4M) [Q4]

6% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 69

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$52
50%
upside
Avg. target
$57
65%
upside
High target
$67
93%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Goldman Sachs
Paul Choi
53% 1-year accuracy
8 / 15 met price target
50%upside
$52
Buy
Maintained
17 Apr 2025
HC Wainwright & Co.
Douglas Tsao
17% 1-year accuracy
30 / 172 met price target
53%upside
$53
Buy
Reiterated
24 Feb 2025
Deutsche Bank
David Hoang
12% 1-year accuracy
2 / 17 met price target
93%upside
$67
Buy
Initiated
11 Feb 2025

Financial journalist opinion

Based on 4 articles about XENE published over the past 30 days

Positive
Seeking Alpha
4 days ago
Xenon- A Later Stage Story
Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium channel mechanism and rapid onset of action could address unmet needs in treatment-resistant epilepsy and potentially depression. Financially stable, Xenon is well-funded into 2027, with potential $1Bn market opportunity if azetukalner succeeds in focal onset seizures and expands into other indications.
Xenon- A Later Stage Story
Positive
Seeking Alpha
2 weeks ago
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
Xenon Pharmaceuticals Inc.'s lead asset, azetukalner (XEN1101), shows promising phase 2b results for focal onset seizures (FOS) and is in phase 3 trials for FOS and PGTCS. Despite failing to meet the primary endpoint in an MDD trial, azetukalner's potential in epilepsy remains strong, with long-term data showing sustained seizure reduction. Financially, Xenon Pharma has a solid cash position, providing a runway of 11–13 quarters, making it an attractive investment at current low prices.
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
Neutral
GlobeNewsWire
2 weeks ago
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology Annual Meeting (AAN 2025), taking place April 5-9, 2025 in San Diego, CA. Three posters will be presented, including long-term data from the ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS). The Company will also present an exploratory efficacy analysis of FOS seizure subtypes from the X-TOLE study, as well as patient survey findings about the mental health and comorbidity burdens of FOS.
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
Neutral
CNBC Television
3 weeks ago
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Neutral
GlobeNewsWire
1 month ago
Xenon to Present at Stifel 2025 Virtual CNS Forum
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025.
Xenon to Present at Stifel 2025 Virtual CNS Forum
Negative
Zacks Investment Research
1 month ago
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Neutral
Seeking Alpha
1 month ago
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Caroline Poacher - JPMorgan Brian Skorney - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Douglas Tsao - H.C. Wainwright Operator Hello and thank you for standing by.
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
Neutral
GlobeNewsWire
1 month ago
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025.
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
Neutral
GlobeNewsWire
1 month ago
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025.
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
Charts implemented using Lightweight Charts™